Mounjaro is one of the most effective medications available for both weight loss and blood sugar control. In clinical trials, people taking the highest dose lost an average of 20.9% of their body weight over 72 weeks, and up to 97% of people with type 2 diabetes reached healthy blood sugar targets. These results outperformed every other medication in its class head-to-head.
How Mounjaro Works Differently
Most medications in this category target a single gut hormone called GLP-1. Mounjaro targets two: GLP-1 and another called GIP. Both hormones are naturally released after you eat, and they work together to trigger insulin release, slow digestion, and reduce appetite. The dual action is what sets Mounjaro apart from drugs like Ozempic or Wegovy, which only activate the GLP-1 pathway.
The GIP component appears to do something insulin alone can’t. Research shows that GIP receptor activation improves how your body responds to insulin through a mechanism that’s independent of weight loss. GIP receptors are also found in fat tissue and metabolic control centers in the brain, which likely contributes to the stronger weight and appetite effects. On the GLP-1 side, Mounjaro activates the receptor in a slightly different way than natural GLP-1, causing less receptor burnout over time. This may help explain why its effects remain robust at higher doses.
Weight Loss Results by Dose
The landmark SURMOUNT-1 trial tested Mounjaro at three doses in people with obesity (without diabetes) over 72 weeks. The average body weight lost compared to placebo was:
- 5 mg dose: 15% of body weight
- 10 mg dose: 19.5% of body weight
- 15 mg dose: 20.9% of body weight
For someone starting at 250 pounds, that highest dose translates to roughly 52 pounds lost over about a year and a half. These numbers represent averages, so some people lost more and some less, but even the lowest dose delivered results that were previously difficult to achieve without surgery.
What to Expect in the First Few Months
Weight loss begins quickly. In the first four weeks, trial participants lost just under 4% of their starting body weight, roughly 1% per week. By week six, that figure reached 5 to 6%, and by week eight, around 6 to 7%. This early pace is partly because you start on a low 2.5 mg dose that gets increased every four weeks, so the medication’s full effect builds gradually. Most people notice reduced appetite and smaller portions within the first few weeks, even at the starting dose.
Blood Sugar Control in Type 2 Diabetes
Mounjaro’s blood sugar results are striking. Across the SURPASS trial program, which enrolled tens of thousands of people with type 2 diabetes, up to 92 to 97% of participants reached an A1C below 7%, which is the standard target for managing diabetes. Even more notable: up to 62% brought their A1C below 5.7%, which is the threshold for people without diabetes at all.
These results held up against tough comparisons. In SURPASS-2, all three Mounjaro doses beat semaglutide (the active ingredient in Ozempic) for both A1C reduction and weight loss. In SURPASS-3, Mounjaro outperformed a carefully adjusted long-acting insulin. And in SURPASS-5, it delivered superior results even when both groups were already using background insulin therapy. No other injectable diabetes medication has matched these numbers across such a range of trial designs.
Cardiovascular and Kidney Benefits
Beyond weight and blood sugar, Mounjaro shows meaningful effects on heart and kidney health. A large analysis following patients for nearly four years found that tirzepatide (Mounjaro’s active ingredient) reduced a combined measure of death, heart attack, stroke, heart failure, and serious kidney problems by 16% compared to another GLP-1 drug, dulaglutide. That comparison is especially notable because dulaglutide itself has proven cardiovascular benefits, meaning Mounjaro improved on an already effective treatment. The benefit held whether researchers included or excluded kidney outcomes from the analysis.
How the Dosing Schedule Works
Mounjaro is a once-weekly injection. You start at 2.5 mg, which is designed purely to let your body adjust and isn’t expected to produce full therapeutic effects on its own. After four weeks, you move up to 5 mg. From there, your dose can increase by 2.5 mg increments every four weeks or longer, up to a maximum of 15 mg, depending on how you respond and what you can tolerate. This gradual ramp-up is deliberate: it minimizes side effects while letting your body adapt to each dose level before moving higher.
Side Effects and Tolerability
Nausea, vomiting, and diarrhea are the most common side effects, especially during the first weeks at each new dose. These are driven by the same gut-slowing mechanism that helps with appetite. The good news is that most people tolerate the medication well enough to stay on it. Across the SURPASS trial program, fewer than 7% of participants discontinued due to gastrointestinal issues. For most people, nausea is worst during the first couple of weeks after a dose increase and then fades as the body adjusts.
What Happens When You Stop
This is the part that gets less attention but matters enormously. The SURMOUNT-4 trial looked at what happened when people who had been taking Mounjaro for 36 weeks were switched to a placebo. One year after stopping, 82% of those switched to placebo had regained more than a quarter of the weight they’d lost. This pattern is consistent with what researchers see across all anti-obesity medications: the underlying biology that drives weight gain doesn’t change, and when the medication is removed, appetite and metabolic signals return to their previous state.
This doesn’t mean the medication “doesn’t work.” It means Mounjaro manages a chronic condition rather than curing it, similar to how blood pressure medication controls hypertension without eliminating it. For most people, sustaining results requires ongoing treatment, and that’s an important factor when weighing cost, access, and long-term planning.